Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice

Infection and Immunity

Volumn 79, Issue 8, 2011, Pages 3455-3464

  Campodónico, Victoria L ^a   Llosa, Nicolas J ^a,b   Bentancor, Leticia V ^a   Maira Litran, Tomas ^a   Pier, Gerald B ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; FLAGELLIN; TOLL LIKE RECEPTOR 5;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFICACY; IMMUNOGENICITY; INNATE IMMUNITY; LUNG INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; RABBIT;

ALGINATES; ANIMALS; ANTIBODIES, BACTERIAL; FEMALE; FLAGELLIN; GLUCURONIC ACID; HEXURONIC ACIDS; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; OPSONIN PROTEINS; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS VACCINES; RABBITS; VACCINES, CONJUGATE;

EID: 79961116779     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00157-11     Document Type: Article

References (51)

1. Adamo, R., S. Sokol, G. Soong, M. I. Gomez, and A. Prince. 2004. Pseudomonas aeruginosa flagella activate airway epithelial cells through asialoGM1 and toll-like receptor 2 as well as toll-like receptor 5. Am. J. Respir. Cell Mol. Biol. 30:627-634.
2. Allewelt, M., F. T. Coleman, M. Grout, G. P. Priebe, and G. B. Pier. 2000. Acquisition of expression of the Pseudomonas aeruginosa ExoU cytotoxin leads to increased bacterial virulence in a murine model of acute pneumonia and systemic spread. Infect. Immun. 68:3998-4004.
3. Anastassiou, E. D., A. C. Mintzas, C. Kounavis, and G. Dimitracopoulos. 1987. Alginate production by clinical nonmucoid Pseudomonas aeruginosa strains. J. Clin. Microbiol. 25:656-659.
4. Arora, S. K., M. Bangera, S. Lory, and R. Ramphal. 2001. A genomic island in Pseudomonas aeruginosa carries the determinants of flagellin glycosylation. Proc. Natl. Acad. Sci. U. S. A. 98:9342-9347.
5. Bates, J. T., A. N. Honko, A. H. Graff, N. D. Kock, and S. B. Mizel. 2008. Mucosal adjuvant activity of flagellin in aged mice. Mech. Ageing Dev. 129:271-281.
6. Bates, J. T., S. Uematsu, S. Akira, and S. B. Mizel. 2009. Direct stimulation of tlr5+/+ CD11c+ cells is necessary for the adjuvant activity of flagellin. J. Immunol. 182:7539-7547.
7. Blohmke, C. J., et al. 2008. Innate immunity mediated by TLR5 as a novel antiinflammatory target for cystic fibrosis lung disease. J. Immunol. 180: 7764-7773.
8. Campodonico, V. L., et al. 2010. Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines. Infect. Immun. 78:746-755.
9. Chitnis, C. E., and D. E. Ohman. 1993. Genetic analysis of the alginate biosynthetic gene cluster of Pseudomonas aeruginosa shows evidence of an operonic structure. Mol. Microbiol. 8:583-590.
10. Cryz, S. J., Jr., E. Furer, and J. U. Que. 1991. Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine. Infect. Immun. 59:45-50.
11. Cuadros, C., F. J. Lopez-Hernandez, A. L. Dominguez, M. McClelland, and J. Lustgarten. 2004. Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect. Immun. 72:2810-2816.
12. Doring, G., C. Meisner, and M. Stern. 2007. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc. Natl. Acad. Sci. U. S. A. 104:11020-11025.
13. Doring, G., and G. B. Pier. 2008. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine 26:1011-1024.
14. Frederiksen, B., C. Koch, and N. Hoiby. 1997. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr. Pulmonol. 23:330-335.
15. Garner, C. V., D. DesJardins, and G. B. Pier. 1990. Immunogenic properties of Pseudomonas aeruginosa mucoid exopolysaccharide. Infect. Immun. 58: 1835-1842.
16. Gibson, R. L., J. L. Burns, and B. W. Ramsey. 2003. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med. 168:918-951.
17. Govan, J. R., and V. Deretic. 1996. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol. Rev. 60:539-574.
18. Honko, A. N., and S. B. Mizel. 2004. Mucosal administration of flagellin induces innate immunity in the mouse lung. Infect. Immun. 72:6676-6679.
19. Honko, A. N., N. Sriranganathan, C. J. Lees, and S. B. Mizel. 2006. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect. Immun. 74:1113-1120.
20. Kashef, N., et al. 2006. Synthesis and characterization of Pseudomonas aeruginosa alginate-tetanus toxoid conjugate. J. Med. Microbiol. 55:1441-1446.
21. Li, Z., et al. 2005. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 293:581-588.
22. Linker, A., and R. S. Jones. 1966. A new polysaccharide resembling alginic acid isolated from pseudomonads. J. Biol. Chem. 241:3845-3851.
23. Lyczak, J. B., C. L. Cannon, and G. B. Pier. 2002. Lung infections associated with cystic fibrosis. Clin. Microbiol. Rev. 15:194-222.
24. Mathee, K., et al. 1999. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology 145:1349-1357.
25. McSorley, S. J., B. D. Ehst, Y. Yu, and A. T. Gewirtz. 2002. Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo. J. Immunol. 169:3914-3919.
26. Miao, E. A., E. Andersen-Nissen, S. E. Warren, and A. Aderem. 2007. TLR5 and Ipaf: dual sensors of bacterial flagellin in the innate immune system. Semin. Immunopathol. 29:275-288.
27. Mizel, S. B., et al. 2009. Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates. Clin. Vaccine Immunol. 16:21-28.
28. Morris, A. E., H. D. Liggitt, T. R. Hawn, and S. J. Skerrett. 2009. Role of Toll-like receptor 5 in the innate immune response to acute P. aeruginosa pneumonia. Am. J. Physiol. Lung Cell. Mol. Physiol. 297:L1112-L1119.
29. Neville, L. F., et al. 2005. Antibodies raised against N'-terminal Pseudomonas aeruginosa flagellin prevent mortality in lethal murine models of infection. Int. J. Mol. Med. 16:165-171.
30. Nivens, D. E., D. E. Ohman, J. Williams, and M. J. Franklin. 2001. Role of alginate and its O acetylation in formation of Pseudomonas aeruginosa microcolonies and biofilms. J. Bacteriol. 183:1047-1057.
31. Parad, R. B., C. J. Gerard, D. Zurakowski, D. P. Nichols, and G. B. Pier. 1999. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infect. Immun. 67:4744-4750.
32. Pawlowski, A., and S. B. Svenson. 1999. Electron beam fragmentation of bacterial polysaccharides as a method of producing oligosaccharides for the preparation of conjugate vaccines. FEMS Microbiol. Lett. 174:255-263.
33. Pier, G. B., et al. 2004. Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains. J. Immunol. 173:5671-5678.
34. Pier, G. B., F. Coleman, M. Grout, M. Franklin, and D. E. Ohman. 2001. Role of alginate O acetylation in resistance of mucoid Pseudomonas aeruginosa to opsonic phagocytosis. Infect. Immun. 69:1895-1901.
35. Pier, G. B., et al. 1994. Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine. Infect. Immun. 62:3972-3979.
36. Pier, G. B., D. Desjardins, T. Aguilar, M. Barnard, and D. P. Speert. 1986. Polysaccharide surface antigens expressed by nonmucoid isolates of Pseudomonas aeruginosa from cystic fibrosis patients. J. Clin. Microbiol. 24:189-196.
37. Pier, G. B., et al. 1987. Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis. N. Engl. J. Med. 317:793-798.
38. Pino, O., M. Martin, and S. M. Michalek. 2005. Cellular mechanisms of the adjuvant activity of the flagellin component FljB of Salmonella enterica serovar Typhimurium to potentiate mucosal and systemic responses. Infect. Immun. 73:6763-6770.
39. Prince, A. 2006. Flagellar activation of epithelial signaling. Am. J. Respir. Cell Mol. Biol. 34:548-551.
40. Ramphal, R., and S. K. Arora. 2001. Recognition of mucin components by Pseudomonas aeruginosa. Glycoconj. J. 18:709-713.
41. Ramphal, R., et al. 2008. Control of Pseudomonas aeruginosa in the lung requires the recognition of either lipopolysaccharide or flagellin. J. Immunol. 181:586-592.
42. Ramsey, D. M., and D. J. Wozniak. 2005. Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic fibrosis. Mol. Microbiol. 56:309-322.
43. Raoust, E., et al. 2009. Pseudomonas aeruginosa LPS or flagellin are sufficient to activate TLR-dependent signaling in murine alveolar macrophages and airway epithelial cells. PLoS One 4:e7259.
44. Russell, N. J., and P. Gacesa. 1988. Chemistry and biology of the alginate of mucoid strains of Pseudomonas aeruginosa in cystic fibrosis. Mol. Aspects Med. 10:1-91.
45. Saha, S., et al. 2007. Blocking of the TLR5 activation domain hampers protective potential of flagellin DNA vaccine. J. Immunol. 179:1147-1154.
46. Schurks, N., J. Wingender, H. C. Flemming, and C. Mayer. 2002. Monomer composition and sequence of alginates from Pseudomonas aeruginosa. Int. J. Biol. Macromol. 30:105-111.
47. Theilacker, C., et al. 2003. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine. Infect. Immun. 71:3875-3884.
48. Verma, A., S. K. Arora, S. K. Kuravi, and R. Ramphal. 2005. Roles of specific amino acids in the N terminus of Pseudomonas aeruginosa flagellin and of flagellin glycosylation in the innate immune response. Infect. Immun. 73:8237-8246.
49. Weimer, E. T., S. E. Ervin, D. J. Wozniak, and S. B. Mizel. 2009. Immunization of young African green monkeys with OprF epitope 8-OprI-type A-and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa. Vaccine 27:6762-6769.
50. Winstanley, C., et al. 2005. Genotypic and phenotypic characteristics of Pseudomonas aeruginosa isolates associated with ulcerative keratitis. J. Med. Microbiol. 54:519-526.
51. Yu, F. S., et al. 2010. Flagellin stimulates protective lung mucosal immunity: role of cathelicidin-related antimicrobial peptide. J. Immunol. 185:1142-1149.